Welcome to our dedicated page for Zymeworks SEC filings (Ticker: ZYME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zymeworks Inc. (Nasdaq: ZYME) SEC filings page on Stock Titan brings together the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K and proxy materials. These documents provide detailed information on financial results, material events, governance matters, and strategic initiatives for this global biotechnology and clinical-stage biopharmaceutical company.
Through its 8-K filings, Zymeworks reports items such as quarterly financial results, material clinical and regulatory milestones, leadership and board changes, share repurchase authorizations, and strategic initiatives related to its asset and royalty aggregation strategy. For example, recent 8-Ks describe positive topline Phase 3 HERIZON-GEA-01 results for Ziihera ® (zanidatamab-hrii), the launch of a share repurchase program, and updates on licensed products and healthcare assets. Other 8-Ks address decisions on specific pipeline programs, such as the voluntary discontinuation of clinical development for ZW171, and amendments to financing instruments like pre-funded warrants.
The company’s definitive proxy statement on Form DEF 14A offers additional insight into Zymeworks’ governance structure, board composition, committee responsibilities, executive compensation practices, and matters submitted to stockholders for approval. Together, these filings help investors understand how Zymeworks oversees its integrated model of internal R&D and royalty-driven asset management.
On Stock Titan, these SEC filings are updated as they become available from EDGAR and are paired with AI-powered summaries that highlight key points, such as revenue drivers, material clinical events, capital structure changes, and governance decisions. Users can quickly scan current and historical filings to track developments affecting Zymeworks’ licensed assets, pipeline programs, cash resources, and shareholder-related actions, without needing to read every page of the underlying documents.
Zymeworks Inc. director Carlos Campoy reported new equity awards. On January 12, 2026 he received stock options covering 11,500 shares of common stock at an exercise price of $23.16 per share, which vest on January 12, 2027. He also received 7,700 restricted stock units, each representing one share of common stock, with the RSUs vesting on January 12, 2027. Following these awards, he directly holds 11,500 stock options and 7,700 RSUs in the company.
Zymeworks Inc. director Susan Mahony reported new equity awards. On January 12, 2026, she was granted stock options covering 11,500 shares of Zymeworks common stock with an exercise price of $23.16 per share. These options vest on January 12, 2027 and are scheduled to expire on January 11, 2036.
She was also granted 7,700 restricted stock units (RSUs) on the same date. Each RSU represents the right to receive one share of common stock upon vesting, and all 7,700 RSUs vest on January 12, 2027. Both the options and RSUs are reported as directly owned by Mahony.
Zymeworks Inc. Chief Scientific Officer Paul Andrew Moore reported multiple equity transactions on January 12, 2026. One third of a prior restricted stock unit (RSU) grant vested, resulting in 17,666 shares of common stock, and 9,560 shares were sold at a weighted average price of $22.6735 solely to cover tax withholding and related fees under a mandatory sell-to-cover provision. After these transactions, he directly held 48,497 shares of common stock.
On the same date, Moore received new equity awards, including 70,000 stock options with a $23.16 exercise price that vest 25% after one year and the rest in 36 monthly installments. He was also granted 47,000 RSUs vesting in four equal annual installments and 66,000 performance stock units, representing the maximum shares that may be earned based on total shareholder return goals over a three-year period ending January 12, 2029, subject to continued service.
Zymeworks Inc. Chair and CEO Kenneth Galbraith reported equity award activity and a tax-related share sale. On January 12, 2026, 64,000 restricted stock units vested and were settled into common shares at $0.00, and 30,424 common shares were sold at a weighted average price of $22.6735 solely to cover tax withholding and fees under mandatory “sell to cover” provisions. After these transactions, he directly held 226,842 common shares.
On the same date, he received new equity awards: a stock option for 216,000 shares at an exercise price of $23.16 expiring on January 11, 2036, which vests 25% after one year and monthly thereafter; a new RSU grant of 144,000 shares vesting in four equal annual installments; and performance stock units covering up to 222,000 shares tied to total shareholder return goals over a three-year period ending January 12, 2029, with 50%–200% of a 111,000-target range potentially earned.
ZYME filed a notice of proposed sale of restricted securities under Rule 144. The notice covers the planned sale of 6,832 shares of common stock through Morgan Stanley Wealth Management Canada on or about 01/12/2026 on the Nasdaq market, with an aggregate market value of
Zymeworks Inc. insider Jeffrey T L Smith has filed a notice of proposed sale of common stock under Rule 144. The filing indicates an intent to sell 9,310 shares of common stock through Morgan Stanley Wealth Management Canada on the Nasdaq, with an aggregate market value of
The securities to be sold were acquired on
Zymeworks Inc. insider Kenneth Galbraith has filed a Form 144 indicating an intention to sell 30,424 shares of common stock on or about 01/12/2026 through Morgan Stanley Wealth Management Canada on Nasdaq, with an aggregate market value of $704,924.08.
The filing shows that 64,000 shares of common stock were acquired on 01/12/2026 through the vesting of restricted stock units from the issuer, with payment described as vesting of an award.
Over the prior three months, the same seller reported two sales of Zymeworks common stock: 47,528 shares on 12/22/2025 for gross proceeds of $1,284,311.12, and 54,343 shares on 01/05/2026 for gross proceeds of $1,363,840.84.
Zymeworks Inc. insider Mark Hollywood has filed a Form 144 notice to sell common stock. The filing covers a planned sale of 6,120 shares of common stock through Morgan Stanley Wealth Management Canada on or about 01/12/2026, with an indicated aggregate market value of $141,800.40. The class is listed on the Nasdaq, and there were 74,836,534 shares of this class outstanding.
The shares to be sold are tied to equity compensation, as 17,666 shares of common stock were acquired on 01/12/2026 through the vesting of restricted stock units granted by the issuer. The filer also reported that, during the prior three months, Mark Hollywood sold 8,911 shares of common stock on 01/05/2026 for gross proceeds of $223,638.47. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about Zymeworks’ current or prospective operations.
Zymeworks Inc. insider trading notice outlines planned and recent share sales. A holder plans to sell 9,560 shares of Zymeworks common stock through Morgan Stanley Wealth Management Canada on or about 01/12/2026, with an aggregate market value of $221,505.20, while 74,836,534 shares of common stock are outstanding. These shares relate to the vesting of 17,666 restricted stock units on 01/12/2026, with vesting noted as the form of payment. The filing also reports that Paul Andrew Moore sold 20,110 shares of common stock on 01/05/2026 for gross proceeds of $504,698.65. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Zymeworks’ operations.
Zymeworks Inc. reported preliminary, unaudited cash resources of about $270.6 million as of December 31, 2025, and said that, based on current plans, it believes it can fund operations beyond 2028 assuming full execution of a $125.0 million share repurchase plan and receipt of $440.0 million in anticipated regulatory milestone payments tied to potential Ziihera approvals in GEA across the United States, Europe, Japan and China. The company also announced multiple leadership changes, including appointing Brian Cherry as a new Class II director, terminating Executive Vice President, Chief Business Officer and Chief Financial Officer Leone Patterson without cause, and naming Chair, President and CEO Kenneth Galbraith as interim Chief Financial Officer. Zymeworks promoted Mark Hollywood to Executive Vice President and Chief Operating Officer with increased salary and new equity awards, and outlined a planned transition in the Chief Medical Officer role from Jeffrey Smith, who is retiring, to Sabeen Mekan.
FAQ
What is the current stock price of Zymeworks (ZYME)?
What is the market cap of Zymeworks (ZYME)?
